obesity drug news today glp-1 october 2025 Alarming rise in weight loss overdoses GLP-1 therapies are changing obesity

In conclusion, GLP-1 provides a novel approach for treating AD, hypertension and NASH

If you are particularly interested in enhanced energy expenditure and fat oxidation via glucagon pathways, mazdutide offers this over tirzepatide GIP-based approach

The market for glucagon-like peptide-1 (GLP-1) agonists has seen tremendous development and transition, driven by a variety of factors that affect its direction

Assuming everyone took it, made no lifestyle changes and gained back more than half of the weight after discontinuation with no use as a maintenance drug afterwards, utilizing a very pessimistic penetration rate of 15%, even then it would be enough to have the obesity rate correct lower by more than 6%

Obesity 28 , 429436 (2019)

2011;9:56776 (e1-4)